[{"abstract": "Bristol-Myers Squibb, the drug maker, said Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer.", "web_url": "https://dealbook.nytimes.com/2010/03/03/management-shuffle-at-bristol-myers/", "snippet": "Bristol-Myers Squibb, the drug maker, said Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer.", "lead_paragraph": "The drug maker Bristol-Myers Squibb said on Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Management Shuffle at Bristol-Myers", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Bristol-Myers Squibb Co", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Medarex Incorporated", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}], "pub_date": "2010-03-03T07:20:49+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Liza Klaussmann", "person": [{"firstname": "Liza", "middlename": null, "lastname": "Klaussmann", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/3c987fae-e2f9-57cc-bd82-04c6498c43e9", "word_count": 169, "uri": "nyt://article/3c987fae-e2f9-57cc-bd82-04c6498c43e9"}, {"abstract": "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer\u2019s and the companies developing the treatment, Medivation and Pfizer.", "web_url": "https://www.nytimes.com/2010/03/04/business/04drug.html", "snippet": "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer\u2019s and the companies developing the treatment, Medivation and Pfizer.", "lead_paragraph": "It seemed somewhat unlikely, but in recent years an old Russian hay fever pill had become one of the world\u2019s best hopes for treating the growing epidemic of Alzheimer\u2019s disease. ", "print_section": "B", "print_page": "2", "source": "The New York Times", "multimedia": [], "headline": {"main": "Hopes for Alzheimer\u2019s Drug Are Dashed", "kicker": null, "content_kicker": null, "print_headline": "As an Alzheimer\u2019s Drug Fails, Hopes Fall", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "subject", "value": "Clinical Trials", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Medivation, Incorporated", "rank": 4, "major": "N"}, {"name": "subject", "value": "Alzheimer's Disease", "rank": 5, "major": "N"}], "pub_date": "2010-03-03T15:45:50+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/199d1b71-01ef-53be-a5af-3121080d7bc1", "word_count": 645, "uri": "nyt://article/199d1b71-01ef-53be-a5af-3121080d7bc1"}, {"abstract": "The Deal Professor examines how the structure of deals has changed and tightened in the wake of the financial crisis, when a number of transactions collapsed.", "web_url": "https://dealbook.nytimes.com/2010/03/03/post-crisis-the-evolving-structure-of-deals/", "snippet": "The Deal Professor examines how the structure of deals has changed and tightened in the wake of the financial crisis, when a number of transactions collapsed.", "lead_paragraph": "In the wake of the financial crisis, deal lawyers have been reconsidering the structure of acquisitions. The result has been a clash of wills between targets and acquirers. Targets have sought to bind acquirers as tightly as possible, seeking to avoid a deal collapse that destroys shares prices,\u00a0 similar to what happened to many targets amid the crisis.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Post-Crisis, the Evolving Structure of Deals", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "ACXIOM CORPORATION", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Dow Chemical Co", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Finish Line Incorporated (The)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Genesco Incorporated", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Mars Inc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "MSCI", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 7, "major": "N"}, {"name": "organizations", "value": "RiskMetrics", "rank": 8, "major": "N"}, {"name": "organizations", "value": "United Rentals Incorporated", "rank": 9, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 10, "major": "N"}], "pub_date": "2010-03-03T16:17:13+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Steven Davidoff Solomon", "person": [{"firstname": "Steven", "middlename": "Davidoff", "lastname": "Solomon", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/5ce44468-2341-5ca5-a4f8-eca04b0b04c2", "word_count": 1588, "uri": "nyt://article/5ce44468-2341-5ca5-a4f8-eca04b0b04c2"}]